CDSCO Releases May 2026 Drug Quality Alert
The Central Drugs Standard Control Organisation (CDSCO) has published its monthly drug quality alert for May 2026, revealing that 157 drug samples were declared Not of Standard Quality (NSQ) and 2 drug samples were identified as Spurious after testing by Central and State Drug Testing Laboratories across India.
The findings highlight the importance of India’s ongoing post-marketing surveillance system, which continuously monitors the quality, safety, and efficacy of medicines available in the market. The latest report includes a wide range of pharmaceutical products, medical devices, and cosmetic products that failed to meet prescribed quality standards.
Major Quality Failures Detected Across Multiple Drug Categories
According to the CDSCO report, several commonly prescribed medicines failed one or more quality parameters, including:
- Dissolution
- Assay
- Sterility
- Microbial Contamination
- Identification Tests
- Related Substances
- Particulate Matter
- Disintegration
- Appearance and Clarity
The affected products include antibiotics, anti-diabetic medicines, cardiovascular drugs, cough syrups, injections, gastrointestinal medicines, and various medical devices.
Leading Pharmaceutical Companies Featured in NSQ List
The report includes batches manufactured by several well-known pharmaceutical companies, including:
- Sun Pharmaceutical Industries
- Alkem Laboratories
- Medreich Limited
- Cipla Limited
- Macleods Pharmaceuticals
- Blue Cross Laboratories
- Cadila Pharmaceuticals
- Wings Biotech
- Taj Pharma India
- Helax Healthcare
- Unicure India
While inclusion in the NSQ list does not necessarily indicate a widespread quality issue across all products from these manufacturers, specific batches failed regulatory testing standards and may be subject to further investigation.
Antibiotic Products Among Major Failures
One of the most notable findings involved multiple batches of Amoxycillin and Potassium Clavulanate Tablets IP, a widely prescribed antibiotic combination.
Batches manufactured by:
- Sun Pharma
- Medreich Limited
- Alkem Health Science
were reported to have failed dissolution and assay tests.
Additionally, a batch manufactured by Apex Formulation failed identification and content requirements and was subsequently classified as a Spurious Drug under the Drugs and Cosmetics Act.
Injectable Medicines Fail Sterility and Assay Standards
Several injectable products were found to be non-compliant with quality requirements:
Ferric Carboxymaltose Injection
- Manufacturer: Maan Pharmaceuticals
- Failure: Bacterial Endotoxin Test
Triamcinolone Acetonide Injection
- Manufacturer: NDB Healthcare
- Failure: Sterility Test
Heparin Sodium Injection
- Manufacturer: Nandani Medical Laboratories
- Failure: Assay Requirements
Ceftriaxone Injection
- Manufacturer: Macleods Pharmaceuticals
- Failure: Appearance, Clarity and Particulate Matter
Iron Sucrose Injection
- Manufacturer: Marc Laboratories
- Failure: pH and Alkalinity Requirements
Such failures are considered significant because injectable medicines bypass the body’s natural defense mechanisms and require strict quality control.
Anti-Diabetic Medicines Also Failed Quality Tests
The May 2026 report identified multiple anti-diabetic products that failed assay and dissolution testing.
Affected formulations included combinations containing:
- Glimepiride
- Metformin
- Voglibose
- Teneligliptin
Manufacturers such as Taj Pharma India and Rivpra Formulation were among those listed in the NSQ report.
Given the widespread use of these medicines among diabetic patients, regulatory authorities may initiate additional investigations and corrective actions where necessary.
Cardiovascular Drugs Found Non-Compliant
Several cardiovascular medicines used in the treatment of hypertension and cholesterol disorders also failed quality testing.
Affected molecules included:
- Telmisartan
- Amlodipine
- Rosuvastatin
Reported failures involved:
- Dissolution
- Related Substances
- Product Description Tests
Quality deviations in cardiovascular medicines can potentially impact therapeutic outcomes, making regulatory surveillance especially important.
Cough Syrups and Respiratory Medicines Fail Assay Requirements
A number of cough and cold formulations manufactured by different companies failed assay tests related to active pharmaceutical ingredients.
The affected ingredients included:
- Ambroxol
- Dextromethorphan
- Menthol
- Phenylephrine
- Guaiphenesin
Manufacturers named in the report include:
- Crest Lifesciences
- Bionexy Pharma
- Dhwanilife Care
- ASPO Pharmaceuticals
Medical Devices and Surgical Products Also Fail Standards
The CDSCO report was not limited to pharmaceutical products.
Several medical and surgical products were also declared Not of Standard Quality, including:
- Absorbent Cotton Wool
- Gauze Bandages
- Roller Bandage Cloth
- Infusion Sets
- Sterile Swabs
Reported failures involved:
- Sterility
- Absorbency
- Dimensions
- Water-Soluble Substances
- Fluorescence Testing
These products play a crucial role in hospitals and healthcare settings, making quality compliance essential.
Cosmetic Products Found Non-Compliant
The quality alert also covered cosmetic products.
A sunscreen lotion manufactured by Elegant Cosmed reportedly failed microbial examination requirements.
Additionally, certain cosmetic products including facewash and lipstick products were declared misbranded under applicable regulations.
Two Drug Samples Declared Spurious
Among the most serious findings of the May 2026 report was the identification of two drug samples as Spurious Drugs.
One of these involved Amoxycillin and Potassium Clavulanate Tablets that failed both identification and content testing requirements.
Spurious drugs pose significant public health risks and are subject to strict regulatory action under the Drugs and Cosmetics Act.
Why This CDSCO Alert Matters
The monthly NSQ and Spurious Drug reports serve several important functions:
- Protect patient safety
- Monitor medicine quality across the supply chain
- Identify manufacturing issues
- Support regulatory enforcement actions
- Improve overall pharmaceutical quality standards
Healthcare institutions, pharmacists, distributors, and wholesalers are advised to verify affected batch numbers and take appropriate action if these products are found in inventory.
Conclusion
The CDSCO May 2026 Drug Quality Alert demonstrates the critical role of post-marketing surveillance in ensuring medicine safety across India. With 157 drug samples declared Not of Standard Quality and 2 classified as Spurious, the report serves as an important reminder of the need for continuous quality monitoring throughout the pharmaceutical supply chain.
Pharmacists, healthcare professionals, distributors, and regulatory authorities should remain vigilant and review the affected batch details to ensure that non-compliant products do not reach patients.
Recommended Products
